| Submit your comments on this article |
| Science & Technology |
| Doctor Reveals that Remdesivir Was the Real Cause For Many Alleged COVID-19 Maladies |
| 2021-09-04 |
| [GreatMountainPublishing] Dr. Bryan Ardis makes an astounding revelation. He states that Dr. Fauci pushed the use of Veklury® (remdesivir) as a treatment for COVID-19 knowing that it would be unsafe and ineffective for patients. Veklury® (remdesivir) is a nucleotide analogue RNA polymerase inhibitor. Dr. Ardis reveals that the symptoms of lungs filling with fluid and the other alleged COVID-19 symptoms were actually side effects of kidney poisoning and other organ damage that are known side-effects of Veklury® (remdesivir). Dr. Ardis alleges that the devestating health toll allegedly caused by COVID-19 was actually caused by the NIH recommended treatment of Veklury® (remdesivir). Dr. Bryan states that the NIH even cited two studies on its website that showed that Veklury® (remdesivir) was ineffective and unsafe to patients. It seems that many doctors just blindly followed the recommendation of the NIH to use Veklury® (remdesivir) without actually reading the cited studies. I tracked down those studies and read them. NIH Recommends Remdesivir On May 12, 2020, the NIH recommended the use of Veklury® (remdesivir) for severe cases of COVID-19. At that time, Veklury® (remdesivir) was an unapproved experimental drug made by Gilead Sciences. It was authorized by the FDA for emergency use treatment of COIVD-19. Conflicts of Interest n my research I discovered something quite disturbing. The recommendation from the NIH to use Veklury® (remdesivir) to treat COVID-19 came from the NIH Panel on COVID-19 Treatment Guidelines. There were nine (9) people on the NIH Panel on COVID-19 Treatment Guidelines with financial ties to Gilead Sciences, the maker of Veklury® (remdesivir). The following is a list of those people on the NIH Panel on COVID-19 Treatment Guidelines who had financial ties to Gilead Sciences, the manufacturer of Veklury® (remdesivir): Rajesh Gandhi is on the advisory board of Gilead Sciences. David Glidden is a consultant for Gilead Sciences. Adaora Adimora is a consultant for Gilead Sciences and received research support from Gilead Sciences. Eric Daar is a consultant for Gilead Sciences and recieves research support from Gilead Sciences. Judith Aberg received research support from Gilead Sciences. Jason Baker received research support from Gilead Sciences. Susanna Naggie received research support from Gilead Sciences. Pablo Tebas received research support from Gilead Sciences. Roger Bedimo received an honoraria from Gilead Sciences. Steering Doctors Away From Hydroxychloroquine The panel tried to steer doctors away from Hydroxychloroquine, by stating that "[t]here are insufficient clinical data to recommend either for or against using chloroquine or hydroxychloroquine for the treatment of COVID." The panel, of course, had an interest in undermining inexpensive and effective treatements: "[T]he Panel recommends against the use of the following drugs for the treatment of COVID-19: The combination of hydroxychloroquine plus azithromycin because of the potential for toxicities." That was not true. Indeed many subsequent studies have shown that the hydroxychloroquine plus azithromycin "combination is safe and may avoid worsening, virus persistence, and subsequent contagiosity." This author previous wrote an article explaining the extreme efforts taken to discredit hydroxychloroquine. Doctors conducting studies purposely administered toxic levels of hydroxychlorquine to falsely show that it was dangerous to patients. Doctors Poisoned Test Patients to Falsely Show that Hydroxychloroquine Is Not Safe and Effective. This is the part I have tried to point out that you can check out for yourself with a copy of the allegedly authoritative study and a 2017 copy of the PDR. Remdesivir Adverse Effects Many of the studies cited in support of NIH’s recommendation to use Veklury® (remdesivir) were in vitro studies or animal studies. A couple of the human studies were at best a mixed bag. Two of the most authoritative studies showed Veklury® (remdesivir) to be ineffective and unsafe. On or about May 12, 2020, the FDA reported the following summary for study GS-US-5773: In a randomized, open-label clinical trial (Study GS-US-540-5773) of remdesivir in 397 subjects with severe COVID-19 treated with remdesivir for 5 (n=200) or 10 days (n=197), adverse events were reported in 71% and 74% of subjects, respectively, serious adverse events were reported in 21% and 35% of subjects, respectively, and Grade=3 adverse events were reported in 31% and 43% of subjects, respectively. Nine (5%) subjects in the 5-day group and 20 (10%) subjects in the 10-day group discontinued treatment due to an adverse event. All cause mortality at Day 28 was 10% vs 13% in the 5- and 10-day treatment groups, respectively.Please do not miss the fact that there were reported 71% adverse events in the 5-day study and 74% adverse events in the 10-day study for patients taking Veklury® (remdesivir). 21% suffered serious adverse events in the 5 day study and 35% of the patients suffered serious adverse events in the 10-day study. Below is the chart of adverse events published in the study. Since I don't have a web host I'm leaving out the chart Hiding Remdesivir Adverse Effects This is where it gets deceptive. In a later published fact sheet dated October 2020, the FDA provided the following summary of that same study: Study GS-US-540-5773 was a randomized, open-label clinical trial in hospitalized adult subjects with severe COVID-19 treated with VEKLURY 200 mg on Day 1 and 100 mg once daily for 5 (n=200) or 10 days (n=197). Adverse reactions were reported in 33 (17%) subjects in the 5-day group and 40 (20%) subjects in the 10-day group. The most common adverse reactions occurring in at least 5% of subjects in either the VEKLURY 5-day or 10-day group, respectively, were nausea (5% vs 3%), AST increased (3% vs 6%), and ALT increased (2% vs 7%). Rates of any adverse reaction, serious adverse reactions, and adverse reactions leading to treatment discontinuation are presented in Table 6. [Chart 6 indicated that 3% of the 5 day group and 5% of the 10 day group had treatment discontinued due to adverse reactions.] Notice the differences in reporting. The May 2020 report describes adverse events, whereas the October 2020 report changes the reporting to adverse reactions. The difference is that an adverse reaction denotes a causal relationship and an adverse event is an event that may or may not be causally related. A reaction is sometimes defined as the response to a medication where that response is at least resonably possible to have been caused by the medication. By concealing the adverse events and only reporting adverse reactions, the October 2020 FDA report conceals the real danger from Veklury® (remdesivir). Keep in mind that an adverse reaction must be established by a reasonable possibility. Such nebulous standards for distinguishing adverse events from adverse reactions are ripe for abuse. An adverse event could be causally related but the reviewer may just decide it is not reasonable to infer it is causally linked, and thus it would not be called an adverse reaction. That should be enough to get started with. Additional sections of the original article, which I suggest you read, include:
|
| Posted by:Thing From Snowy Mountain |
| #4 This scene keeps going through my head, guys. I think I need a criminal lawyer. |
| Posted by: Thing From Snowy Mountain 2021-09-04 12:50 |
| #3 I think I'd have to find an American lawyer for that question who's more familiar with common law and that sort of thing. |
| Posted by: Thing From Snowy Mountain 2021-09-04 12:43 |
| #2 Can they be sued? |
| Posted by: Knuckles Ulavising9510 2021-09-04 12:15 |
| #1 When Pharma companies come up with something new, we gotta try it out. Else how will you know what it won't do? (I mean, TV ads for drugs, without telling you what it's supposed to be for?) |
| Posted by: ed in texas 2021-09-04 10:57 |